Share Price and Basic Stock Data
Last Updated: January 27, 2026, 9:45 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Achyut Healthcare Ltd operates within the pharmaceuticals sector, showcasing a modest market capitalization of ₹132 Cr. The company’s stock price stood at ₹5.59. A review of the company’s revenue trends illustrates significant fluctuations. For instance, sales recorded in Mar 2022 were ₹4.05 Cr, which sharply declined to ₹2.70 Cr in Mar 2023 before rebounding to ₹6.14 Cr in Mar 2024. The trailing twelve months (TTM) revenue reached ₹6.56 Cr. Quarterly sales figures also demonstrate volatility, with a peak of ₹5.64 Cr anticipated in Sep 2025, following a low of ₹0.81 Cr in Mar 2023. This inconsistency may reflect challenges in demand or operational inefficiencies. The company’s operating profit margin (OPM) fluctuated significantly, recording a low of -35.80% in Mar 2023, indicating operational challenges, before stabilizing at 2.66% in Sep 2025. This trend underscores the need for strategic adjustments to enhance revenue stability and growth.
Profitability and Efficiency Metrics
Achyut Healthcare’s profitability indicators reveal a challenging landscape. The net profit for the fiscal year ending Mar 2025 was ₹0.55 Cr, with a net profit margin of 17.97%, reflecting a recovery from prior lows. However, the return on equity (ROE) stood at a mere 1.77%, suggesting limited profitability relative to shareholder equity. The company reported an interest coverage ratio of 3596.50x, indicating no interest-bearing debt, which is a positive aspect of its financial structure. Efficiency metrics also highlight a cash conversion cycle (CCC) of 40.81 days, which, while manageable, indicates potential inefficiencies in capital management. The operating profit margin (OPM) remained low throughout the period, with a notable negative figure of -35.80% in Mar 2023, suggesting operational inefficiencies. Overall, while there are signs of recovery, the company must enhance its operational effectiveness to improve profitability sustainably.
Balance Sheet Strength and Financial Ratios
Achyut Healthcare’s balance sheet displays significant strength, particularly with no reported borrowings across the examined periods. Total assets as of Mar 2025 were ₹32.59 Cr, supported by reserves of ₹7.98 Cr, which reflects a gradual build-up from ₹7.74 Cr in Mar 2025. The company’s equity capital increased from ₹6.74 Cr in Mar 2022 to ₹23.56 Cr in Mar 2025, indicating a strong capital base. The price-to-book value ratio stood at 2.45x, suggesting the market values the shares at a premium compared to the book value. Additionally, liquidity ratios such as the current ratio at 9.32 and quick ratio at 9.18 indicate robust short-term financial health, far exceeding typical sector norms. However, the company must convert these strengths into operational performance to leverage its financial position effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Achyut Healthcare reveals a mixed landscape of investor confidence. As of Sep 2025, promoters held a 47.07% stake, down from 66.18% in Mar 2022, indicating a gradual reduction in promoter control. Meanwhile, foreign institutional investors (FIIs) held 5.26%, a notable increase from 0% prior to Mar 2024, reflecting growing interest from international investors. Public shareholding stood at 47.67%, indicating a balanced distribution among retail investors. The increase in the number of shareholders from 245 in Mar 2022 to 565 in Sep 2025 suggests rising interest in the company, potentially bolstered by its improved financial metrics. However, the decline in promoter shareholding may raise concerns regarding long-term commitment and strategy. Investor confidence appears cautiously optimistic, with the presence of institutional investors providing a stabilizing influence.
Outlook, Risks, and Final Insight
Looking ahead, Achyut Healthcare faces both opportunities and challenges. The company’s recent revenue growth signals potential for recovery, but sustained profitability remains a concern, particularly given its low ROE and fluctuating profit margins. Key risks include operational inefficiencies, as evidenced by inconsistent OPM figures, and reliance on a limited product portfolio. Additionally, the declining promoter stake may signal uncertainty regarding the company’s strategic direction. If Achyut Healthcare can streamline operations and enhance product offerings, it may capitalize on its strong balance sheet and investor interest to drive growth. Conversely, failure to address operational challenges could hinder its ability to leverage financial strengths effectively. The next fiscal periods will be critical in determining whether the company can transform its promising financial metrics into consistent operational success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 197/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,466 Cr. | 316 | 479/192 | 71.8 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.2 Cr. | 46.1 | 83.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 64.1 Cr. | 43.7 | 43.7/17.0 | 153 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,551.42 Cr | 1,082.84 | 47.19 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.71 | 1.34 | 1.89 | 0.81 | 1.48 | 4.65 | 2.13 | 0.92 | 5.64 |
| Expenses | 2.56 | 1.53 | 1.87 | 1.10 | 1.45 | 4.66 | 2.21 | 1.04 | 5.49 |
| Operating Profit | 0.15 | -0.19 | 0.02 | -0.29 | 0.03 | -0.01 | -0.08 | -0.12 | 0.15 |
| OPM % | 5.54% | -14.18% | 1.06% | -35.80% | 2.03% | -0.22% | -3.76% | -13.04% | 2.66% |
| Other Income | 0.02 | 0.13 | 0.23 | 0.36 | 0.32 | 0.41 | 0.56 | 0.36 | 0.20 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.03 |
| Profit before tax | 0.17 | -0.07 | 0.25 | 0.07 | 0.35 | 0.40 | 0.47 | 0.24 | 0.32 |
| Tax % | 47.06% | -28.57% | 0.00% | 114.29% | 22.86% | 20.00% | 25.53% | 16.67% | 25.00% |
| Net Profit | 0.09 | -0.05 | 0.24 | -0.01 | 0.26 | 0.31 | 0.35 | 0.20 | 0.23 |
| EPS in Rs | 0.01 | -0.00 | 0.02 | -0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Last Updated: December 28, 2025, 9:33 am
Below is a detailed analysis of the quarterly data for Achyut Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 5.64 Cr.. The value appears strong and on an upward trend. It has increased from 0.92 Cr. (Mar 2025) to 5.64 Cr., marking an increase of 4.72 Cr..
- For Expenses, as of Sep 2025, the value is 5.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.04 Cr. (Mar 2025) to 5.49 Cr., marking an increase of 4.45 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from -0.12 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.27 Cr..
- For OPM %, as of Sep 2025, the value is 2.66%. The value appears strong and on an upward trend. It has increased from -13.04% (Mar 2025) to 2.66%, marking an increase of 15.70%.
- For Other Income, as of Sep 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.36 Cr. (Mar 2025) to 0.20 Cr., marking a decrease of 0.16 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.32 Cr.. The value appears strong and on an upward trend. It has increased from 0.24 Cr. (Mar 2025) to 0.32 Cr., marking an increase of 0.08 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.67% (Mar 2025) to 25.00%, marking an increase of 8.33%.
- For Net Profit, as of Sep 2025, the value is 0.23 Cr.. The value appears strong and on an upward trend. It has increased from 0.20 Cr. (Mar 2025) to 0.23 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.01. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:20 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.67 | 0.33 | 0.27 | 4.05 | 2.70 | 6.14 | 3.05 | 6.56 |
| Expenses | 0.66 | 0.32 | 0.26 | 4.08 | 2.97 | 6.12 | 3.25 | 6.53 |
| Operating Profit | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.20 | 0.03 |
| OPM % | 1.49% | 3.03% | 3.70% | -0.74% | -10.00% | 0.33% | -6.56% | 0.46% |
| Other Income | 0.00 | 0.01 | 0.00 | 0.14 | 0.59 | 0.73 | 0.92 | 0.56 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 |
| Profit before tax | 0.01 | 0.02 | 0.01 | 0.10 | 0.31 | 0.74 | 0.70 | 0.56 |
| Tax % | 300.00% | 0.00% | 0.00% | 60.00% | 25.81% | 32.43% | 22.86% | |
| Net Profit | -0.01 | 0.01 | 0.01 | 0.04 | 0.23 | 0.50 | 0.55 | 0.43 |
| EPS in Rs | -0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 200.00% | 0.00% | 300.00% | 475.00% | 117.39% | 10.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 300.00% | 175.00% | -357.61% | -107.39% |
Achyut Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 56% |
| 3 Years: | -9% |
| TTM: | -50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 123% |
| 3 Years: | 140% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 88% |
| 1 Year: | 44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 10, 2025, 3:43 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 6.74 | 9.35 | 16.83 | 23.56 | 23.56 |
| Reserves | -0.05 | -0.04 | 0.00 | 2.34 | 5.18 | 13.93 | 7.74 | 7.98 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.04 | 0.06 | 0.25 | 0.86 | 0.81 | 0.19 | 1.29 | 2.48 |
| Total Liabilities | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 | 34.02 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.06 | 0.03 | 0.26 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 3.49 | 9.16 | 18.19 | 24.38 |
| Investments | 0.00 | 0.00 | 0.00 | 1.70 | 1.30 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.24 | 0.27 | 0.50 | 8.21 | 10.50 | 21.73 | 14.37 | 9.38 |
| Total Assets | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 | 34.02 |
Below is a detailed analysis of the balance sheet data for Achyut Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 23.56 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 23.56 Cr..
- For Reserves, as of Sep 2025, the value is 7.98 Cr.. The value appears strong and on an upward trend. It has increased from 7.74 Cr. (Mar 2025) to 7.98 Cr., marking an increase of 0.24 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2.48 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.29 Cr. (Mar 2025) to 2.48 Cr., marking an increase of 1.19 Cr..
- For Total Liabilities, as of Sep 2025, the value is 34.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.59 Cr. (Mar 2025) to 34.02 Cr., marking an increase of 1.43 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 0.26 Cr., marking an increase of 0.23 Cr..
- For CWIP, as of Sep 2025, the value is 24.38 Cr.. The value appears strong and on an upward trend. It has increased from 18.19 Cr. (Mar 2025) to 24.38 Cr., marking an increase of 6.19 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 9.38 Cr.. The value appears to be declining and may need further review. It has decreased from 14.37 Cr. (Mar 2025) to 9.38 Cr., marking a decrease of 4.99 Cr..
- For Total Assets, as of Sep 2025, the value is 34.02 Cr.. The value appears strong and on an upward trend. It has increased from 32.59 Cr. (Mar 2025) to 34.02 Cr., marking an increase of 1.43 Cr..
Notably, the Reserves (7.98 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 54.48 | 188.03 | 378.52 | 18.02 | 36.50 | 24.37 | 160.36 |
| Inventory Days | 0.00 | 0.00 | 158.70 | 14.29 | 59.59 | 3.96 | 24.16 |
| Days Payable | 380.87 | 41.78 | 55.87 | 12.54 | 143.71 | ||
| Cash Conversion Cycle | 54.48 | 188.03 | 156.34 | -9.46 | 40.22 | 15.79 | 40.81 |
| Working Capital Days | 76.27 | 210.15 | 216.30 | 603.83 | 1,257.22 | 1,242.43 | 1,169.20 |
| ROCE % | 9.76% | 4.35% | 2.14% | 2.63% | 3.27% | 2.26% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.02 | 0.34 | 0.31 | 0.15 | 0.30 |
| Diluted EPS (Rs.) | 0.02 | 0.34 | 0.31 | 0.15 | 0.30 |
| Cash EPS (Rs.) | 0.02 | 0.34 | 0.25 | 0.06 | 0.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.33 | 18.28 | 15.54 | 13.48 | 8.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.33 | 18.28 | 15.54 | 13.48 | 8.68 |
| Revenue From Operations / Share (Rs.) | 0.12 | 3.65 | 2.88 | 6.01 | 10.91 |
| PBDIT / Share (Rs.) | 0.03 | 0.44 | 0.33 | 0.15 | 0.42 |
| PBIT / Share (Rs.) | 0.02 | 0.44 | 0.33 | 0.15 | 0.42 |
| PBT / Share (Rs.) | 0.02 | 0.44 | 0.33 | 0.14 | 0.40 |
| Net Profit / Share (Rs.) | 0.02 | 0.34 | 0.24 | 0.05 | 0.29 |
| PBDIT Margin (%) | 23.60 | 12.24 | 11.78 | 2.62 | 3.85 |
| PBIT Margin (%) | 23.09 | 12.11 | 11.54 | 2.49 | 3.85 |
| PBT Margin (%) | 23.08 | 12.07 | 11.48 | 2.48 | 3.74 |
| Net Profit Margin (%) | 17.97 | 9.34 | 8.57 | 0.99 | 2.71 |
| Return on Networth / Equity (%) | 1.74 | 1.86 | 1.59 | 0.44 | 3.41 |
| Return on Capital Employeed (%) | 2.24 | 2.41 | 2.14 | 1.11 | 4.83 |
| Return On Assets (%) | 1.68 | 1.85 | 1.50 | 0.40 | 1.57 |
| Asset Turnover Ratio (%) | 0.09 | 0.26 | 0.21 | 0.77 | 0.73 |
| Current Ratio (X) | 9.32 | 106.66 | 12.68 | 9.46 | 1.82 |
| Quick Ratio (X) | 9.18 | 106.38 | 12.29 | 9.31 | 1.44 |
| Inventory Turnover Ratio (X) | 25.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3596.50 | 375.85 | 186.88 | 169.54 | 35.00 |
| Interest Coverage Ratio (Post Tax) (X) | 2739.50 | 287.60 | 137.00 | 65.14 | 25.67 |
| Enterprise Value (Cr.) | 75.79 | 87.10 | 50.86 | 13.59 | 0.00 |
| EV / Net Operating Revenue (X) | 24.87 | 14.19 | 18.87 | 3.36 | 0.00 |
| EV / EBITDA (X) | 105.37 | 115.87 | 160.10 | 127.69 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 25.20 | 14.25 | 18.96 | 3.42 | 0.00 |
| Price / BV (X) | 2.45 | 2.84 | 3.52 | 1.52 | 0.00 |
| Price / Net Operating Revenue (X) | 25.21 | 14.26 | 18.96 | 3.42 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Achyut Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 1.00, marking a decrease of 9.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 3. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.33. It has decreased from 18.28 (Mar 24) to 1.33, marking a decrease of 16.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.33. It has decreased from 18.28 (Mar 24) to 1.33, marking a decrease of 16.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.12. It has decreased from 3.65 (Mar 24) to 0.12, marking a decrease of 3.53.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.44 (Mar 24) to 0.03, marking a decrease of 0.41.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.02, marking a decrease of 0.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.02, marking a decrease of 0.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For PBDIT Margin (%), as of Mar 25, the value is 23.60. This value is within the healthy range. It has increased from 12.24 (Mar 24) to 23.60, marking an increase of 11.36.
- For PBIT Margin (%), as of Mar 25, the value is 23.09. This value exceeds the healthy maximum of 20. It has increased from 12.11 (Mar 24) to 23.09, marking an increase of 10.98.
- For PBT Margin (%), as of Mar 25, the value is 23.08. This value is within the healthy range. It has increased from 12.07 (Mar 24) to 23.08, marking an increase of 11.01.
- For Net Profit Margin (%), as of Mar 25, the value is 17.97. This value exceeds the healthy maximum of 10. It has increased from 9.34 (Mar 24) to 17.97, marking an increase of 8.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.74. This value is below the healthy minimum of 15. It has decreased from 1.86 (Mar 24) to 1.74, marking a decrease of 0.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.24. This value is below the healthy minimum of 10. It has decreased from 2.41 (Mar 24) to 2.24, marking a decrease of 0.17.
- For Return On Assets (%), as of Mar 25, the value is 1.68. This value is below the healthy minimum of 5. It has decreased from 1.85 (Mar 24) to 1.68, marking a decrease of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.09. It has decreased from 0.26 (Mar 24) to 0.09, marking a decrease of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 9.32. This value exceeds the healthy maximum of 3. It has decreased from 106.66 (Mar 24) to 9.32, marking a decrease of 97.34.
- For Quick Ratio (X), as of Mar 25, the value is 9.18. This value exceeds the healthy maximum of 2. It has decreased from 106.38 (Mar 24) to 9.18, marking a decrease of 97.20.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 25.09. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 25.09, marking an increase of 25.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3,596.50. This value is within the healthy range. It has increased from 375.85 (Mar 24) to 3,596.50, marking an increase of 3,220.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2,739.50. This value is within the healthy range. It has increased from 287.60 (Mar 24) to 2,739.50, marking an increase of 2,451.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 75.79. It has decreased from 87.10 (Mar 24) to 75.79, marking a decrease of 11.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 24.87. This value exceeds the healthy maximum of 3. It has increased from 14.19 (Mar 24) to 24.87, marking an increase of 10.68.
- For EV / EBITDA (X), as of Mar 25, the value is 105.37. This value exceeds the healthy maximum of 15. It has decreased from 115.87 (Mar 24) to 105.37, marking a decrease of 10.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 25.20. This value exceeds the healthy maximum of 3. It has increased from 14.25 (Mar 24) to 25.20, marking an increase of 10.95.
- For Price / BV (X), as of Mar 25, the value is 2.45. This value is within the healthy range. It has decreased from 2.84 (Mar 24) to 2.45, marking a decrease of 0.39.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 25.21. This value exceeds the healthy maximum of 3. It has increased from 14.26 (Mar 24) to 25.21, marking an increase of 10.95.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Achyut Healthcare Ltd:
- Net Profit Margin: 17.97%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.24% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.74% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2739.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 9.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 47.19)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.97%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 610, Colonade, B/H Iscon Temple, Opposite Iscon, BRTS Bus Stand, Ahmedabad Gujarat 380058 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra C Raycha | Chairman & Non-Exe.Director |
| Mr. Jigen J Modi | Managing Director |
| Ms. Amisha J Modi | Executive Director |
| Mr. Akshit Raycha | Non Executive Director |
| Mr. Rutvik S Thakkar | Independent Director |
| Mrs. Sonu L Jain | Independent Director |
| Mr. Paragkumar S Dave | Independent Director |
| Mr. Rajesh C Sutaria | Independent Director |
FAQ
What is the intrinsic value of Achyut Healthcare Ltd?
Achyut Healthcare Ltd's intrinsic value (as of 27 January 2026) is ₹0.29 which is 94.66% lower the current market price of ₹5.43, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹128 Cr. market cap, FY2025-2026 high/low of ₹6.57/2.82, reserves of ₹7.98 Cr, and liabilities of ₹34.02 Cr.
What is the Market Cap of Achyut Healthcare Ltd?
The Market Cap of Achyut Healthcare Ltd is 128 Cr..
What is the current Stock Price of Achyut Healthcare Ltd as on 27 January 2026?
The current stock price of Achyut Healthcare Ltd as on 27 January 2026 is ₹5.43.
What is the High / Low of Achyut Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Achyut Healthcare Ltd stocks is ₹6.57/2.82.
What is the Stock P/E of Achyut Healthcare Ltd?
The Stock P/E of Achyut Healthcare Ltd is .
What is the Book Value of Achyut Healthcare Ltd?
The Book Value of Achyut Healthcare Ltd is 1.33.
What is the Dividend Yield of Achyut Healthcare Ltd?
The Dividend Yield of Achyut Healthcare Ltd is 0.00 %.
What is the ROCE of Achyut Healthcare Ltd?
The ROCE of Achyut Healthcare Ltd is 2.26 %.
What is the ROE of Achyut Healthcare Ltd?
The ROE of Achyut Healthcare Ltd is 1.77 %.
What is the Face Value of Achyut Healthcare Ltd?
The Face Value of Achyut Healthcare Ltd is 1.00.